Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Discontinuing PJP prophylaxis while on prednisone doses greater than 12.5 mg per day may elevate infection risk among patients with rheumatic diseases.

Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

The EULAR updated their recommendations for antirheumatic drug use among patients with RMDs during pregnancy and fertility ...

A low dose combination hormonal patch was found to be effective for pregnancy prevention based on results from a phase 3 study.

The use of HCQ among patients with SSc appears to be low and is not associated with improvements in hand function or activities of daily living.

Use of a combined oral contraceptive (COC) is not associated with asthma in women of reproductive age, but use of a progestogen-only pill (POP) is associated with an increased risk for asthma attacks ...

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

Osteoboost, a targeted vibration therapy device, is now available to improve bone strength and bone density in postmenopausal women.

Live zoster vaccination is associated with a lower risk for overall cardiovascular events when compared with no vaccination.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Results of the updated systematic review informing the 2024 EULAR recommendations showed that many ARDs are safe to use during pregnancy, lactation, and reproduction.